Type I interferon pathway activation in connective tissue disease associated interstitial lung disease - Takeaways - MDSpire

Type I interferon pathway activation in connective tissue disease associated interstitial lung disease

  • By

  • Tobias M. Defesche

  • Thomas Koudstaal

  • Marjan A. Versnel

  • Odilia B.J. Corneth

  • Zana Brkic

  • June 11, 2026

  • 0 min

Share

  • 1

    Interstitial lung disease (ILD) is prevalent in connective tissue diseases (CTDs) and accounts for 25-30% of all ILD cases.

  • 2

    Up to 40% of ILDs are progressive, characterized by lung function decline and increased symptoms despite standard immunosuppressive therapy.

  • 3

    Type I interferon (IFN-I) signaling is implicated in the pathophysiology of CTD-ILD, correlating with accelerated pulmonary decline.

  • 4

    Anifrolumab, an anti-IFNAR monoclonal antibody, is under clinical investigation for its potential in treating CTD-ILD.

  • 5

    Current treatment strategies for CTD-ILD include immunosuppression and antifibrotics, but many patients continue to progress.

Original Source(s)

Type I interferon pathway activation in connective tissue disease associated interstitial lung disease

  • by Tobias M. Defesche, Thomas Koudstaal, Marjan A. Versnel, Odilia B.J. Corneth, Zana Brkic

  • June 11, 2026

Related Content

Anti-CD146 Linked to Silica in Systemic Sclerosis

Comparative analysis across exposed workers, cancer controls, and healthy donors supports specificity.

AMA Backs Structured Vaccine Review

Medical societies and public health groups will collaborate on policy questions and evidence briefs for the 2026 to 2027 respiratory virus season.

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.